Grace Therapeutics (GRCE)

• Market cap: $31.7M
• 1 day: -2.38%
• 5 days: -52.87%
• 1 month: -52.98%
• 3 months: -41.6%
• 6 months: -34.5%
• Year to date: -43.99%
• 1 year: -19.92%
• 5 years: -91.38%
• 10 years: -96.97%
• Sector: Healthcare
• Industry: Biotechnology

About: Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.

Employees: 6